Reasons to Retain Fresenius Medical Stock in Your Portfolio for Now

Fresenius Medical Care AG & Co. FMS is well-positioned for growth, backed by strong profitability improvements from its FME25+ transformation program and growing momentum in value-based care, and innovation-driven expansion through the 5008X CAREsystem rollout. However, regulatory headwinds, flat treatment volumes and weakness in China remain key concerns.

Shares of this Zacks Rank #3 (Hold) company have dropped 12.5% over the past six months compared with the industry’s 3.6% decline. However, the S&P 500 Index has increased 0.6% in the same timeframe.

The company, with a market capitalization of $12.7 billion, is one of the largest integrated providers of products and services for individuals undergoing dialysis following chronic kidney failure. Its bottom line is anticipated to improve 4.3% over the next five years. FMS’ earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 9.7%.

Image Source: Zacks Investment Research

Factors Favoring FMS Stock’s Growth

FME25+ Transformation Driving Margin Expansion: Fresenius Medical’s FME25+ transformation program continues to be a central driver of profitability and operational efficiency. In 2025, the company exceeded its upgraded savings targets, delivering EUR 238 million in incremental savings and reaching a total of EUR 804 million in cumulative sustainable savings. This strong execution supported a significant margin expansion, with group margins rising to 11.3% for the full year of 2025 and 13.9% in fourth-quarter 2025 alone. The program’s impact spans across supply chain optimization, manufacturing efficiencies and clinic footprint rationalization, helping offset inflationary pressures and rising labor costs. With plans to expand the program further and target EUR 1.2 billion in total savings by 2027, FME25+ remains a key lever for sustained earnings growth and margin resilience.

5008X CAREsystem Rollout & Innovation in Kidney Care: Fresenius Medical is entering a new growth phase driven by the large-scale rollout of its 5008X CAREsystem, which is expected to transform dialysis treatment through high-volume hemodiafiltration. The company has initiated deployment across U.S. clinics and plans to convert around 20% of its installed base in 2026. This transition is expected to improve patient outcomes, reduce mortality and enhance operational efficiency over time. While the financial benefits will ramp up gradually, management highlighted that improved clinical outcomes and reduced missed treatments will support volume recovery and long-term growth. This innovation-led strategy strengthens FMS’ competitive positioning and aligns with its broader FME Reignite plan focused on quality-driven growth.

Strong Value-Based Care Momentum & Earnings Inflection: Fresenius Medical is seeing accelerating momentum in its Value-Based Care segment, which generated over EUR 2 billion in revenues in 2025 and achieved a milestone by reaching breakeven profitability for the full year. The segment posted strong 42% organic growth in fourth-quarter 2025, driven by expanding patient membership and increased contracting activity. This business is transitioning from a historically loss-making position to a contributor to earnings, supported by improved savings rates and operational efficiencies. As FMS continues to scale its provider network and deepen its presence in coordinated care models, Value-Based Care is emerging as a long-term growth driver.

Factors That May Offset FMS’ Gains

Regulatory Headwinds & TDAPA Phase-Out: Fresenius Medical faces notable regulatory headwinds heading into 2026, particularly from the phase-out of temporary benefits under the TDAPA (Transitional Drug Add-on Payment Adjustment) program. In 2025, these benefits contributed to earnings, including around EUR 220 million from phosphate binders and additional contributions from antimicrobial catheter solutions. However, management expects a EUR 150-200 million earnings headwind as these benefits begin to phase out. While some of these revenues will remain within the system, the high base created in 2025 makes year-over-year comparisons challenging and could pressure near-term earnings growth.

Flat Treatment Volumes & Elevated Missed Treatments: Patient volume growth remains a concern, with the same market treatment growth in the United States expected to remain flat in 2026. Volumes continue to be affected by elevated missed treatments, lingering impacts from higher mortality rates and external factors such as weather disruptions and seasonal flu patterns. Although management expects a recovery to 2%+ growth over time, supported by improved patient outcomes and quality initiatives, the near-term outlook remains cautious. This lack of volume growth limits revenue expansion and creates uncertainty around the pace of recovery in the core dialysis business.

China Regulatory Pressure & Rising Cost Inflation: Fresenius Medical’s Care Enablement segment is facing ongoing challenges in China due to regulatory changes, including volume-based procurement policies and stricter tender requirements. These factors resulted in an estimated EUR 50 million negative impact on EBIT in 2025 and are expected to persist in 2026, although at a reduced level. Management indicated that China contributed a notable drag, with regulatory and tender-related issues affecting performance.

At the same time, FMS continues to face elevated cost pressures across its global operations. Management expects EUR 200-300 million in inflationary cost headwinds in 2026, including around 3% labor cost increases, alongside higher medical benefit costs that exceeded initial expectations in 2025. While FMS is mitigating these pressures through efficiency measures under its FME25+ program, the scale of cost inflation remains substantial. Together, these regulatory challenges and rising costs are expected to pressure margins and limit earnings growth in the near term, despite ongoing efforts to improve operational efficiency.

Fresenius Medical Care AG & Co. KGaA Price

Fresenius Medical Care AG & Co. KGaA price | Fresenius Medical Care AG & Co. KGaA Quote

Estimate Trend

The Zacks Consensus Estimate for 2026 revenues is pegged at $23.44 billion, indicating 5.7% year-over-year growth. The consensus mark for earnings is pinned at $2.49 per share, implying growth of 2.9% from the year-ago level.

Key Picks

Some top-ranked stocks from the broader medical space are Phibro Animal Health PAHC, Intuitive Surgical ISRG and Cardinal Health CAH.

Phibro Animal Health, currently sporting a Zacks Rank #1 (Strong Buy), reported second-quarter fiscal 2026 adjusted EPS of 87 cents, which surpassed the Zacks Consensus Estimate by 27.1%. Revenues of $373.9 million beat the Zacks Consensus Estimate by 4.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.

PAHC has an estimated long-term earnings growth rate of 21.5% compared with the industry’s 12.4% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 20.1%.

Intuitive Surgical, carrying a Zacks Rank #2 (Buy) at present, reported fourth-quarter 2025 adjusted earnings per share (EPS) of $2.53, beating the Zacks Consensus Estimate by 12.4%. Revenues of $2.87 billion surpassed the Zacks Consensus Estimate by 4.7%.

ISRG has an estimated long-term earnings growth rate of 15.7% compared with the industry’s 13.6% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 13.2%.

Cardinal Health, currently carrying a Zacks Rank #2, reported a second-quarter fiscal 2026 adjusted EPS of $2.63, which surpassed the Zacks Consensus Estimate by 10%. Revenues of $65.6 billion beat the Zacks Consensus Estimate by 0.9%.

CAH has an estimated long-term earnings growth rate of 15% compared with the industry’s 9.2% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 9.3%.

Radical New Technology Could Hand Investors Huge Gains

Quantum Computing is the next technological revolution, and it could be even more advanced than AI.

While some believed the technology was years away, it is already present and moving fast. Large hyperscalers, such as Microsoft, Google, Amazon, Oracle, and even Meta and Tesla, are scrambling to integrate quantum computing into their infrastructure.

Senior Stock Strategist Kevin Cook reveals 7 carefully selected stocks poised to dominate the quantum computing landscape in his report, Beyond AI: The Quantum Leap in Computing Power.

Kevin was among the early experts who recognized NVIDIA's enormous potential back in 2016. Now, he has keyed in on what could be "the next big thing" in quantum computing supremacy. Today, you have a rare chance to position your portfolio at the forefront of this opportunity.

See Top Quantum Stocks Now >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Intuitive Surgical, Inc. (ISRG): Free Stock Analysis Report

Cardinal Health, Inc. (CAH): Free Stock Analysis Report

Fresenius Medical Care AG & Co. KGaA (FMS): Free Stock Analysis Report

Phibro Animal Health Corporation (PAHC): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research